Diagnostic and therapeutic approaches in the treatment of gastric cancer – a scoping review
DOI:
https://doi.org/10.2478/AMB-2026-0035Keywords:
gastric cancer, H. Pylori, pathoanatomy, staging, treatmentAbstract
Abstract. Gastric carcinoma poses a significant clinical challenge and remains one of the leading causes of cancer-related mortality worldwide. Accurate classification of these tumors based on their histology, anatomical location, and molecular characteristics is essential, as it dictates both prognosis and therapeutic strategy. Objective: to review the key classification systems that underpin the current understanding and treatment of gastric cancer, and to analyze new approaches to diagnosis and treatment through a systematic review of scientific publications. Materials and Methods: we conducted a scoping review by searching for scientific publications in various sources – databases and printed literature, articles, textbooks, monographs, etc. Results and Discussion:
Lauren’s histological classification distinguishes between intestinal and diffuse types, which have different etiologies and prognoses. The anatomical location, especially the distinction between cardia and non-cardia cancer, is also important. The evolving understanding of its biology, including the key role of H. pylori, hereditary syndromes, such as HDGC, and the clinical significance of TCGA molecular subtypes, has been changing the epidemiological landscape and shaping the current paradigm of multidisciplinary, multimodal treatment. Radical surgical treatment and adequate lymph node dissection determine the outcome of the disease. Advances in perioperative systemic treatments and a personalized approach based on biomarkers, such as MSI status for immunotherapy, improve treatment outcomes.
References
Chung HW, Lim JB. Role of the tumor microenvironment in the pathogenesis of gastric carcinoma. World J Gastroenterol. 2014;20(7):1667-80.
Piazuelo MB, Correa P. Gastric cáncer: Overview. Colomb Med (Cali). 2013;44(3):192-201.
Machlowska J, Baj J, Sitarz M, Maciejewski R, Sitarz R. Gastric Cancer: Epidemiology, Risk Factors, Classification, Genomic Characteristics and Treatment Strategies. Int J Mol Sci. 2020;21(11):4012.
Kim YI, Kim YA, Lee H, et al. Clinical significance of four molecular subtypes of gastric cancer identified by The Cancer Genome Atlas project. Oncotarget. 2017;9(5):5961-5973.
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249.
Lin JL, Lin JX, Li P, et al. Global incidence and mortality trends of gastric cancer and predicted mortality of gastric cancer by 2035. BMC Public Health. 2024;24(1):1763.
Siewert JR, Stein HJ. Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg. 1998;85(11):1457-9.
Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet. 2020;396(10251):635-648.
Anderson WF, Rabkin CS, Turner N, et al. The changing face of noncardia gastric cancer incidence among US non-hispanic whites. J Natl Cancer Inst. 2018;110(6):608–615.
Camargo MC, Anderson WF, King JB, et al. Divergent trends for gastric cancer incidence by anatomical subsite in US adults. Gut. 2011;60(12):1644–1649.
Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 2010;11(5):439-49.
Ramachandran R, Grantham T, Singh S et al. Gastric Cancer: Clinical Features, Screening, Diagnosis, Treatment, and Prevention. Cureus. 2024;16(3):e55598.
StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Gastric Cancer. [Updated 2024 Apr 24]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK459142/
Prognosis and Treatment of Gastric Cancer: A 2024 Update. J Clin Med. 2024;13(9):2748.
Sun K, Jia K, Lv H et al. EBV-Positive Gastric Cancer: Current Knowledge and Future Perspectives. Front Oncol. 2020;10:583463.
Lee YY, Derakhshan MH. Environmental and lifestyle risk factors of gastric cancer. Arch Iran Med. 2013;16(6):358-65.
Ilic M, Ilic I. Epidemiology of stomach cancer. World J Gastroenterol. 2022;28(12):1187-1203.
Larsson SC, Bergkvist L, Wolk A. Fruit and vegetable consumption and incidence of gastric cancer: a prospective study. Cancer Epidemiol Biomarkers Prev. 2006;15(10):1998-2001.
Wang Q, Chen Y, Wang X, et al. Consumption of fruit, but not vegetables, may reduce risk of gastric cancer: results from a meta-analysis of cohort studies. Eur J Cancer. 2014;50(8):1498-509.
Ferro A, Costa AR, Morais S, et al. Fruits and vegetables intake and gastric cancer risk: a pooled analysis within the Stomach cancer Pooling Project. Int J Cancer. 2020;147(11):3090-3101.
Piazuelo MB, Correa P. Atrophic gastritis: a state-of-the-art overview. Am J Gastroenterol. 2021;116(6):1126-1140.
Figueiredo J, Melo S, Carneiro P, et al. Clinical spectrum and pleiotropic nature of CDH1 germline mutations. J Med Genet. 2019;56(4):199-208.
Syngal S, Brand RE, Church JM, et al. ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol. 2015;110(2):223-62.
Fujitani K, Yang HK, Mizusawa J, et al. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet Oncol. 2016;17(3):309-18.
van Hootegem SJM, Chmelo J, van der Sluis PC, et al. The yield of diagnostic laparoscopy with peritoneal lavage in gastric adenocarcinoma: a retrospective cohort study. Eur J Surg Oncol. 2024;50(3):108233.
Leake PA, Cardoso R, Seevaratnam R, et al. A systematic review of the accuracy and indications for diagnostic laparoscopy prior to curative-intent resection of gastric cancer. Gastric Cancer. 2012;15 Suppl 1:S38-47.
Lordick F, Carneiro F, Cascinu S, et al. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(10):1005-1020.
Tibshirani R. The Lasso Method for Variable Selection in the Cox Model. Stat Med. 1997;16(4):385–95.
Wang Q, Liu G, Hu C. Molecular Classification of Gastric Adenocarcinoma. Gastroenterology Res. 2019;12(6):275-282.
Costa M, Fernandes CL, Magalhães H. Perioperative Treatment in Gastric Cancer: A Fast-Changing Field. Cancers (Basel). 2024;16(23):4036.
Yuan SQ, Nie RC, Jin Y, et al. Perioperative toripalimab and chemotherapy in locally advanced gastric or gastro-esophageal junction cancer: A randomized phase 2 trial. Nat Med. 2024;30(2):552-559.
Derks S, Liao X, Chiaravalli AM, et al. Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers. Oncotarget. 2016;7(22):32925-32
Zhang C, Li D, Yu R, et al. Immune Landscape of Gastric Carcinoma Tumor Microenvironment Identifies a Peritoneal Relapse Relevant Immune Signature. Front Immunol. 2021;12:651033.
Iliopoulos D, Hirsch HA, Struhl K. An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell. 2009;139(4):693-706.
Tye H, Kennedy CL, Najdovska M, et al. STAT3-driven upregulation of TLR2 promotes gastric tumorigenesis independent of tumor inflammation. Cancer Cell. 2012;22(4):466-78.
Ernst M, Najdovska M, Grail D, et al. STAT3 and STAT1 mediate IL-11-dependent and inflammation-associated gastric tumorigenesis in gp130 receptor mutant mice. J Clin Invest. 2008;118(5):1727-38.
Bollrath J, Phesse TJ, von Burstin VA, et al. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell. 2009;15(2):91-102.
Yasumoto K, Koizumi K, Kawashima A, et al. Role of the CXCL12/CXCR4 axis in peritoneal carcinomatosis of gastric cancer. Cancer Res. 2006;66(4):2181-7.
D‘Angelica M, Gonen M, Brennan MF et al. Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann Surg. 2004;240(5):808-16.
van Hootegem SJM, Guchelaar NAD, van der Sluis K, et al. Staging laparoscopy for gastric cancer: European consensus. Br J Surg. 2025;112(9):znaf144.
Wanebo HJ, Kennedy BJ, Chmiel J et al. Cancer of the stomach. A patient care study by the American College of Surgeons. Ann Surg. 1993;218(5):583-92.
Darou-e-Kolaie MK, Hosseini K, Kamali-Sarvestani E. Sister Mary Joseph nodule-A case report with review of literature. J Res Med Sci. 2011;16(1):105-8.
Hamid K, Hamza M, Rezac L, Shrestha A. Linitis Plastica. S D Med. 2022;75(8):375.
Aurello P, Petrucciani N, Antolino L, et al. Lauren histologic type is the most important factor associated with pattern of recurrence following resection of gastric adenocarcinoma. Medicine (Baltimore). 2017;96(29):e7578.
American Cancer Society. Stomach (Gastric) Cancer Stages. Available from: https://www.cancer.org/cancer/types/stomach-cancer/detection-diagnosis-staging/staging.html
Kim JH, Jun KH, Jung H, et al. Prognostic Value of Preoperative Serum Levels of Five Tumor Markers (Carcinoembryonic Antigen, CA19-9, Alpha-fetoprotein, CA72-4, and CA125) in Gastric Cancer. Hepatogastroenterology. 2014;61(132):863-9.
van der Sluis K, Taylor SN, Kodach LL, et al. Tumor-positive peritoneal cytology in patients with gastric cancer is associated with poor outcome: a nationwide study. Eur J Cancer. 2024;199:113541.
Wanebo HJ, Kennedy BJ, Chmiel J, et al. Cancer of the stomach. A patient care study by the American College of Surgeons. Ann Surg. 1993;218(5):583-92.
Andre T, Tougeron D, Piessen G, et al. Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized DNA Mismatch Repair-Deficient/Microsatellite Instability-High Gastric or Gastroesophageal Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study. J Clin Oncol. 2023;41(2):255-265.
Paraneoplastic Syndromes. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK507890/
Graham DY, Schwartz JT, Cain GD, Gyorkey F. Prospective evaluation of biopsy number in the diagnosis of esophageal and gastric carcinoma. Gastroenterology. 1982;82(2):228-31.
British Society of Gastroenterology guidelines on the diagnosis and management of patients at risk of gastric adenocarcinoma. Gut. 2019;68(9):1545-1575.
Lim JS, Yun MJ, Kim MJ, et al. CT and PET in stomach cancer: preoperative staging and monitoring of response to therapy. Radiographics. 2006;26(1):143-56.
Burbidge S, Mahadya K, Naik K. The role of CT and staging laparoscopy in the staging of gastric cancer. Clin Radiol. 2013;68(3):251-5.
Akcakaya A, Alimoglu O. The role of laparoscopic staging for the management of gastric cancer. Prz Gastroenterol. 2020;15(4):329-335.
Leake P-A, Cardoso R, Seevaratnam R, et al. A systematic review of the accuracy and indications for diagnostic laparoscopy prior to curative-intent resection of gastric cancer. Gastric Cancer. 2012;15(1):S38-S47.
Yang AP, Liu J, Lei HY, et al. CA72-4 combined with CEA, CA125 and CAl9-9 improves the sensitivity for the early diagnosis of gastric cancer. Clin Chim Acta. 2014;437:183-6.
Jin Y, Wang H, Chen X, et al. Evaluation of the value of combined detection of tumor markers CA724, carcinoembryonic antigen, CA242, and CA19-9 in gastric cancer. Medicine (Baltimore). 2024;103(19):e37989.
Guo J, Chen S, Li S, et al. A novel classifier based on three preoperative tumor markers predicting the cancer-specific survival of gastric cancer (CEA, CA19-9 and CA72-4). Oncotarget. 2018;9(6):4814-4822.
Cancer Research UK. Survival for stomach cancer. Available at: https://www.cancerresearchuk.org/about-cancer/stomach/cancer/survival
de Vos tot Nederveen Cappel W, Nagengast FM, Griffioen G, et al. Surveillance for hereditary nonpolyposis colorectal cancer: a long-term study of 114 families. Dis Colon Rectum. 2002;45(12):1588-94.
Wei T, Wu Z, Chen Y, et al. Comparison of uncut Roux-en-Y anastomosis and Billroth-II with Braun anastomosis after distal gastrectomy. Front Surg. 2024;11:1356502.
Marano L, Braccio B, Schettino M, et al. Sutureless jejuno-jejunal anastomosis in gastric cancer patients: a comparison with handsewn procedure in a single institute. BMC Surg. 2012;12 Suppl 1:S27.
Svendsen LB, Larsen TM. Nutritional consequences of gastrectomy. Ugeskr Laeger. 2012;174(38):2191-4.
Heo YJ, Park JM, Kim SH, et al. Postoperative metabolic and nutritional derangements after total gastrectomy in gastric cancer пatients. J Gastric Cancer. 2018;18(3):264-273.
Tey CJ, Poon D, Toh E, et al. Endoscopic palliation and nutritional support in advanced gastric cancer. JGH Open. 2018;3(2):161-167.
National Comprehensive Cancer Network. NCCN Guidelines for Patients: Stomach Cancer. 2023. Available from: https://www.nccn.org/patients/guidelines/content/PDF/stomach/patient.pdf
Pachiadakis I, Tsilimigras DI, Schizas D, Moris D. Palliative management of malignant gastric outlet obstruction: An evidence-based review. World J Gastrointest Endosc. 2020;12(12):503-514.
Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687-97.
He CZ, Zhang KH, Li Q, et al. Combined use of AFP, CEA, CA125 and CAl9-9 improves the sensitivity for the diagnosis of gastric cancer. BMC Gastroenterol. 2013;13:87.
Giampieri R, Cantini L, Bittoni A, et al. The role of biologic and targeted therapies in the treatment of elderly patients with advanced gastric cancer. Expert Opin Biol Ther. 2016;16(2):179-91.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 K. Angelov, N. Nachev, E. Yordanov, S. Stoyanova, N. Khayat, A. Sharkov, A. Zlatarov, T. Dyulgerov (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
You are free to share, copy and redistribute the material in any medium or format under these terms.
Journal Acta Medica Bulgarica 
